Read Larry Connors' blog – Short Term Trading Strategies
MEDIA RELEASE PR36707
Novo Nordisk Wins Design Award for NovoTwist(TM) Needle
COPENHAGEN, Oct. 26 /PRNewswire-AsiaNet/ --
Novo Nordisk has been awarded a Good Design Award(TM)(1) for NovoTwist(TM), the new needle designed for use with the insulin delivery device FlexPen(R). The needle, which has a simple 'just twist' attachment and detachment, makes injection easier for people with diabetes.
The Good Design Award(TM) (also known as G-Mark Award)(1) from the Japan Industrial Design Promotion Organization is a mark of true quality and gives recognition to the uniqueness of NovoTwist(TM). Nearly 3,000 entries were narrowed down by the judging panel and NovoTwist(TM) was selected for an award in the 'Society - Medical Equipment' section.(1) Previous winners of the Good Design Award(TM) include Apple, Toshiba, Toyota and Nintendo. The Good Design Award(TM)(1) highlights the unique design features of NovoTwist(TM). The judges specifically commented that "Conventional screw thread needles can be difficult to attach and detach, especially for the elderly, as limited manual dexterity and hand strength make the circular motion of screw attachment/detachment challenging. NovoTwist(TM) has solved this problem with a simple functional design with a push-and- twist needle attachment/detachment system."
When used with FlexPen(R), three out of four patients prefer NovoTwist(TM) to conventional needles,(2) and patients find NovoTwist(TM) easier to use, less timeconsuming and more user-friendly than conventional needles.(2,3) These benefits may be important to people with diabetes who seek easier and more discreet methods of self-administering insulin.
"Given the general anxiety that some people with diabetes can suffer when using any injection device, the new developments with NovoTwist(TM) are a big step forward in terms of user-friendliness," says diabetes nurse Barbel Sommavilla (Diabetes Education Center, Salzburg, Austria) who was involved in a key study assessing patients' preference for insulin pen needles. According to Sommavilla et al 2008, the needle is preferred by people with diabetes.(2)
Novo Nordisk has a long tradition of innovative design. In 2005, the insulin pen NovoPen(R)(4) was also given a Good Design Award(TM),(4) and in 2007, the pen was winner of a red dot product design award.(5) Last year, the NovoFine(R) Autocover(R) needle from Novo Nordisk was awarded a Medical Design Excellence Award.(6)
About NovoTwist(TM)
NovoTwist(TM) comes in 5 mm (32G Tip) and 8 mm (30G), and its novel bayonet fitting allows the user to twist the needle onto FlexPen(R). An audible and tactile 'click' confirms attachment of the needle. An integral glue tower minimises the risk of needle breakage, and short, thin needles ensure safe insulin deposition and reduce injection pain and bruising.(7-11)
For more information on NovoTwist(TM), please visit http:/ tinyurl.com/yjj3d8p
About the Good Design Award(TM)
The Good Design Awards is a comprehensive programme for the evaluation and encouragement of design, organised by Japan Industrial Design Promotion Organization. The award's parent organisation is the Good Design Products Selection System (commonly known as the G-Mark system), established in 1957 by the then Ministry of International Trade and Industry (the current Ministry of Economy, Trade and Industry).
For more information on the G-Mark Awards, please visit http://www.g-mark.org.
Novo Nordisk is a healthcare company and a world leader in diabetes care. In addition, Novo Nordisk has a leading position within areas such as haemostasis management, growth hormone therapy and hormone replacement therapy. Novo Nordisk manufactures and markets pharmaceutical products and services that make a significant difference to patients, the medical profession and society. With headquarters in Denmark, Novo Nordisk employs more than 28,500 employees in 81 countries, and markets its products in 179 countries. Novo Nordisk's B shares are listed on the stock exchanges in Copenhagen and London. Its ADRs are listed on the New York Stock Exchange under the symbol 'NVO'. For more information, visit http://novonordisk.com.
References
1. http://www.g-mark.org/english/archive/2009/outline.html
2. Sommavilla et al. Expert Opin Pharmacother 2008; 9: 2223-32.
3. Lytzen & Ostfeldt. American Diabetes Association 69th Scientific
Sessions; 2009; 1985-PO.
4. http://www.chi-athenaeum.org/gdesign/winners05.htm
5. Data on file, Novo Nordisk A/S.
6. http://tinyurl.com/ylekesm
7. Hofman et al. Diabet Med 2007; 24: 1400-5.
8. Birkebaek et al. Diabet Care 2008; 31: e65.
9. Solvig et al. Diabetes 2001; 50 (Suppl. 2): A123.
10. Iwanaga & Kamoi. Diabetes Technol Ther 2009; 11: 81-6.
11. McKay et al. Diabetes Technol Ther 2009; 11: 195-201.
SOURCE: Novo Nordisk
bl
More News:
Market Updates |
Stock Alerts |
All Trading News |
Stock Index
About TradingMarkets | Contact | Advertise | Careers | Link to Us | Site Map | Help | Terms & Conditions | Privacy Policy | Return Policy | Testimonials | Feedback
The Connors Group, Inc. ("Company") is not an investment advisory service, nor a registered investment advisor or broker-dealer and does not purport to tell or suggest which securities or currencies customers should buy or sell for themselves. The analysts and employees or affiliates of Company may hold positions in the stocks, currencies or industries discussed here. You understand and acknowledge that there is a very high degree of risk involved in trading securities and/or currencies. The Company, the authors, the publisher, and all affiliates of Company assume no responsibility or liability for your trading and investment results. Factual statements on the Company's website, or in its publications, are made as of the date stated and are subject to change without notice.
It should not be assumed that the methods, techniques, or indicators presented in these products will be profitable or that they will not result in losses. Past results of any individual trader or trading system published by Company are not indicative of future returns by that trader or system, and are not indicative of future returns which be realized by you. In addition, the indicators, strategies, columns, articles and all other features of Company's products (collectively, the "Information") are provided for informational and educational purposes only and should not be construed as investment advice. Examples presented on Company's website are for educational purposes only. Such set-ups are not solicitations of any order to buy or sell. Accordingly, you should not rely solely on the Information in making any investment. Rather, you should use the Information only as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments. You should always check with your licensed financial advisor and tax advisor to determine the suitability of any investment.
HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN INHERENT LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING AND MAY NOT BE IMPACTED BY BROKERAGE AND OTHER SLIPPAGE FEES. ALSO, SINCE THE TRADES HAVE NOT ACTUALLY BEEN EXECUTED, THE RESULTS MAY HAVE UNDER- OR OVER-COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFITS OR LOSSES SIMILAR TO THOSE SHOWN.
The Connors Group, Inc.
10 Exchange Place, Suite 1800
Jersey City, NJ 07302
© Copyright 2009 The Connors Group, Inc.
